Publicaciones en las que colabora con Leire Garate Iturriagagoitia (43)

2024

  1. An automated network-based tool to search for metabolic vulnerabilities in cancer

    Nature Communications , Vol. 15, Núm. 1

  2. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Revealing cell populations catching the early stages of human embryo development in naive pluripotent stem cell cultures

    Stem Cell Reports, Vol. 18, Núm. 1, pp. 64-80

2022

  1. Identifying Lethal Dependencies with HUGE Predictive Power

    Cancers, Vol. 14, Núm. 13

  2. Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts

    American Journal of Hematology

2021

  1. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

    Leukemia, Vol. 35, Núm. 5, pp. 1438-1450

  2. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with in Vivo Efficacy in Multiple Myeloma

    Journal of Medicinal Chemistry, Vol. 64, Núm. 6, pp. 3392-3426

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

  2. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression

    Journal of Urology

2019

  1. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

  2. Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6546-6573

  2. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6518-6545

2017

  1. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism

    Nature Communications, Vol. 8, Núm. 1

  2. In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer

    Scientific Reports, Vol. 7, Núm. 1

  3. Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome

    PLoS ONE, Vol. 12, Núm. 12

2013

  1. Erratum: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia (Oncogene (2013) 32 (803) DOI: 10.1038/onc.2012.593)

    Oncogene

  2. Erratum: Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia (Oncogene (2013) 32 (804) DOIi: 10.1038/onc.2012.592)

    Oncogene

2012

  1. Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: Implications in TNFα regulation and proliferation of hematopoietic progenitor cells

    Blood, Vol. 119, Núm. 13, pp. 3042-3049

  2. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia (Blood (2007) 109, 8 (3462-3469))

    Blood